American Journal of Cardiology
Volume 102, Issue 11 , Pages 1489-1494 , 1 December 2008

Efficacy and Safety of Ezetimibe Added on to Atorvastatin (20 mg) Versus Uptitration of Atorvastatin (to 40 mg) in Hypercholesterolemic Patients at Moderately High Risk for Coronary Heart Disease†

  • Scott E. Conard, MD

      Affiliations

    • University of Texas Southwestern Medical School, Dallas, Texas
    • Corresponding Author InformationCorresponding author: Tel: 972-739-3098; fax: 214-570-2544
    • ,
  • Harold E. Bays, MD

      Affiliations

    • Louisville Metabolic and Atherosclerosis Research Center, Louisville, Kentucky
    • ,
  • Lawrence A. Leiter, MD

      Affiliations

    • St. Michael's Hospital and University of Toronto, Toronto, Ontario, Canada
    • ,
  • Steven R. Bird, MS

      Affiliations

    • Merck & Company, Inc., North Wales, Pennsylvania
    • ,
  • Joseph Rubino, MBA

      Affiliations

    • Merck & Company, Inc., North Wales, Pennsylvania
    • ,
  • Robert S. Lowe, PhD

      Affiliations

    • Merck & Company, Inc., North Wales, Pennsylvania
    • ,
  • Joanne E. Tomassini, PhD

      Affiliations

    • Merck & Company, Inc., North Wales, Pennsylvania
    • ,
  • Andrew M. Tershakovec, MD

      Affiliations

    • Merck & Company, Inc., North Wales, Pennsylvania

Received 9 September 2008 ,Revised 29 September 2008 ,Accepted 29 September 2008.

References 

  1. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. J Am Coll Cardiol. 2004;44:720–732
  2. Daskalopoulou SS, Mikhailidis DP. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe. Curr Med Res Opin. 2006;22:511–528
  3. Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation. 2003;107:2409–2415
  4. Davidson MH, Ballantyne CM, Kerzner B, Melani L, Sager PT, Lipka L, et al. Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int J Clin Pract. 2004;58:746–755
  5. Goldberg AC, Sapre A, Liu J, Capece R, Mitchel YB. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc. 2004;79:620–629
  6. Mikhailidis DP, Sibbring GC, Ballantyne CM, Davies GM, Catapano AL. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin. 2007;23:2009–2026
  7. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112:2735–2752
  8. Liang KY, Zeger SL. Longitudinal data analysis of continuous and discrete responses for pre-post designs. Sankya Ser B. 2000;62:134–148
  9. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4:213–226
  10. Leiter LA, Bays H, Conard S, Bird S, Rubino J, Hanson ME, et al. Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease. Am J Cardiol. 2008;102:Epub ahead of print. doi:10.1016/jamjcard.2008.08.076
  11. Ballantyne CM, Blazing MA, King TR, Brady WE, Palmisano J. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol. 2004;93:1487–1494
  12. Bays HE, Neff D, Tomassini JE, Tershakovec AM. Ezetimibe: cholesterol lowering and beyond. Exp Rev Cardiovasc Ther. 2008;6:447–470
  13. Stein E, Stender S, Mata P, Sager P, Ponsonnet D, Melani L, et al. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Am Heart J. 2004;148:447–455
  14. Blagden MD, Chipperfield R. Efficacy and safety of ezetimibe co-administered with atorvastatin in untreated patients with primary hypercholesterolaemia and coronary heart disease. Curr Med Res Opin. 2007;23:767–775

 This study was supported by Merck/Schering-Plough Pharmaceuticals, North Wales, Pennsylvania.

PII: S0002-9149(08)01669-X

doi: 10.1016/j.amjcard.2008.09.075

American Journal of Cardiology
Volume 102, Issue 11 , Pages 1489-1494 , 1 December 2008

Article Tools

* Image Usage & Resolution